COMMUNIQUÉS West-GlobeNewswire

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
28/01/2025
Dual-Targeted CD19/CD70 Allogeneic CAR T: Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications Innovative Dagger ® Technology: Empowers ALLO [...]
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
28/01/2025
Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumors CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies [...]
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
28/01/2025
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further studies aim to [...]
Polarean and SimonMed Announce Collaboration to Advance Lung Imaging Innovation
28/01/2025
One of the largest US outpatient medical imaging providers to introduce Xenon MRI platform to its network DURHAM, NC and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “ [...]
Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
28/01/2025
Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity requirement Evaxion has currently restored its equity above the [...]
FOXO TECHNOLOGIES, INC., PROVIDES UPDATE ON RECENT ACOMPLISHMENTS AND BUSINESS STRATEGY
28/01/2025
MINNEAPOLIS, MN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), provides a brief shareholder letter from Seamus Lagan, recently appointed CEO of FOXO on what has been [...]
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
28/01/2025
Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient settings. [...]
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
28/01/2025
Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating [...]
Lighthouse Autism Center Announces New Location in South Sioux City, Nebraska, creating 35 Jobs and Serving 25 Families
28/01/2025
Leading ABA Provider Set to Open Newest Location in South Sioux City, NE SOUTH SIOUX CITY, Neb., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Lighthouse Autism Center, South Sioux City, Nebraska, a leading provider of center-based [...]
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
28/01/2025
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
28/01/2025
Appoints Simon Harnest as Chief Financial Officer to advance capital markets and corporate development strategy supporting TOS-358, the Company’s lead covalent PI3Kα inhibitor, and additional programs EMERYVILLE, Calif [...]
LifeMD to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
28/01/2025
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the 12 th Annual BTIG MedTech, Digital Health, Life [...]
Telix Completes Acquisition of RLS (USA) Inc.
27/01/2025
MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition of RLS (USA) Inc. (RLS [...]
Dentsply Sirona to Host Fourth Quarter and Full Year 2024 Conference Call on February 27th
27/01/2025
CHARLOTTE, N.C., Jan. 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast [...]
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
27/01/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
27/01/2025
SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the [...]
IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies
27/01/2025
Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”) has launched Ignite Proteomics LLC (“Ignite”), its new subsidiary dedicated to helping doctors [...]
Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast
27/01/2025
GARDEN CITY, N.Y., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares
27/01/2025
NOT FOR DISTRIBUTION TO UNITED STATES TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight [...]

Pages